TMPRSS2-ERG rearrangement is a genetic alteration exclusive to prostate cancer,
associated with taxane resistance in preclinical models. Its detection in blood samples of …

TMPRSS2‐ERG expression in blood has been correlated with low docetaxel benefit in
metastatic castration‐resistant prostate cancer (mCRPC). This multicenter study aimed to …

BACKGROUND: Abiraterone acetate (AA) is an androgen biosynthesis inhibitor shown to
prolong life in patients with castration-resistant prostate cancer (CRPC) already treated with …

We aimed to evaluate ERG and SOX9 as potential biomarkers of docetaxel response in
metastatic castration-resistant prostate cancer (mCRPC) patients. Seventy-one mCRPC …

BACKGROUND The TMPRSS2‐ERG gene fusion is detected in approximately half of
primary prostate cancers (PCa) yet the prognostic significance remains unclear. We …

Recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS
transcription factor family members ERG, ETV1, and ETV4 have been identified as a critical …

It seems clear that androgen receptor (AR)–regulated expression of the TMPRSS2: ERG
fusion gene plays an early role in prostate cancer (PC) development or progression, but the …

3. Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, Iversen P. The predictive
value of ERG protein expression for development of castration-resistant prostate cancer in …

TMPRSS2-ERG has been proposed to be a prognostic marker for prostate cancer. The aim
of this study was to identify changes in metabolism, genes and biochemical recurrence …

Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30%
to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate …